Suda Ltd Stock Australian S.E.
Equities
EMS
AU000000EMS2
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- AUD | - |
06-13 | Arovella Therapeutics, Teva Pharmaceuticals End ZolpiMist License Agreement | MT |
06-05 | Arovella Therapeutics Completes Process Development for ALA-101 Manufacturing; Shares Jump 9% | MT |
Sales 2022 | 296K 196K 268K | Sales 2023 | 1.45M 962K 1.32M | Capitalization | 42.5M 28.11M 38.57M |
---|---|---|---|---|---|
Net income 2022 | -8M -5.29M -7.26M | Net income 2023 | -10M -6.61M -9.08M | EV / Sales 2022 | 32 x |
Net cash position 2022 | 5.93M 3.92M 5.38M | Net cash position 2023 | 5.18M 3.42M 4.7M | EV / Sales 2023 | 25.7 x |
P/E ratio 2022 |
-1.47
x | P/E ratio 2023 |
-3.49
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 91.45% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Baker
CEO | Chief Executive Officer | - | 20-01-01 |
Tim Luscombe
DFI | Director of Finance/CFO | - | 11-30 |
Michelle Long
ADM | Chief Administrative Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Phillips
BRD | Director/Board Member | 62 | 22-06-30 |
Elizabeth Stoner
BRD | Director/Board Member | 73 | 21-11-09 |
Thomas Duthy
CHM | Chairman | - | 23-03-12 |
1st Jan change | Capi. | |
---|---|---|
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- ALA Stock
- EMS Stock